0000000000535372

AUTHOR

Mara Morelli

showing 5 related works from this author

Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI)

2018

Abstract Introduction ROMEI (CINC424AIT04 Ruxolitinib Observational study in Myelofibrosis treated patiEnts in Italy) is a prospective observational study that aims to bridge the knowledge gap between the clinical experience of registration trials and routine patient management by following roughly 200 myelofibrosis (MF) patients (pts) treated with ruxolitinib in everyday clinical practice. Enrollment began in April 2017 and ended in May 2018. Methods The primary endpoint is to evaluate changes in symptoms and quality of life during treatment with ruxolitinib through the Myeloproliferative Neoplasm 10 (MPN-10) disease-specific questionnaire and EuroQoL-5D-5L (EQ-5D-5L) general health questi…

Ruxolitinibmedicine.medical_specialtybusiness.industrySurrogate endpointImmunologyCell BiologyHematologyInterim analysismedicine.diseaseBiochemistryTolerabilityQuality of lifeInternal medicinemedicineClinical endpointbusinessAdverse effectMyelofibrosismedicine.drugBlood
researchProduct

Predictors of enhancing human physical attractiveness: Data from 93 countries

2022

People across the world and throughout history have gone to great lengths to enhance their physical appearance. Evolutionary psychologists and ethologists have largely attempted to explain this phenomenon via mating preferences and strategies. Here, we test one of the most popular evolutionary hypotheses for beauty-enhancing behaviors, drawn from mating market and parasite stress perspectives, in a large cross-cultural sample. We also test hypotheses drawn from other influential and non-mutually exclusive theoretical frameworks, from biosocial role theory to a cultural media perspective. Survey data from 93,158 human participants across 93 countries provide evidence that behaviors such as a…

Objectification TheoryREDES SOCIAISSEX-DIFFERENCESSelf-modificationEvolution:Humanidades::Outras Humanidades [Domínio/Área Científica]Facial Attractiveness:Ciências Médicas::Ciências da Saúde [Domínio/Área Científica]Social SciencesExperimental and Cognitive Psychology:Ciências Sociais::Psicologia [Domínio/Área Científica]Evolutionary PerspectiveSelf-ObjectificationPathogen stressEVOLUTIONARY PERSPECTIVESocial media usageArts and Humanities (miscellaneous)Behavior and Systematicsddc:150Womens Body-ImageMating market perspective:Ciências Naturais::Ciências Biológicas [Domínio/Área Científica]WOMENS BODY-IMAGEEcology Evolution Behavior and SystematicsOBJECTIFICATION THEORYM-PSI/05 - PSICOLOGIA SOCIALEEvolutionary theory ; Mating market perspective ; Pathogen stress ; Appearance ; Self-modification ; Social media usageGender-RoleEcologyMATE PREFERENCES:Samfunnsvitenskap: 200 [VDP]Mate PreferencesEvolutionary theoryPERSONAL ORNAMENTSAppearanceSELF-OBJECTIFICATIONGENDER-ROLEAppearance; Evolutionary theory; Mating market perspective; Pathogen stress; Self-modification; Social media usageSettore M-PSI/05 - PSICOLOGIA SOCIALESocial Media UseSOCIAL MEDIA USESex-DifferencesVDP::Samfunnsvitenskap: 200FACIAL ATTRACTIVENESS:Ciências Naturais::Ciências da Terra e do Ambiente [Domínio/Área Científica]Pathogen strePersonal Ornaments
researchProduct

Predictors of enhancing human physical attractiveness: Data from 93 countries

2022

People across the world and throughout history have gone to great lengths to enhance their physical appearance. Evolutionary psychologists and ethologists have largely attempted to explain this phenomenon via mating preferences and strategies. Here, we test one of the most popular evolutionary hypotheses for beauty-enhancing behaviors, drawn from mating market and parasite stress perspectives, in a large cross-cultural sample. We also test hypotheses drawn from other influential and non-mutually exclusive theoretical frameworks, from biosocial role theory to a cultural media perspective. Survey data from 93,158 human participants across 93 countries provide evidence that behaviors such as a…

Social media usageSelf-modificationEvolutionary theoryAppearanceMating market perspectivePathogen stre
researchProduct

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI…

2021

ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25–40% and 26–36%, respec…

Cancer Researchmedicine.medical_specialtyRuxolitinib8-item Morisky Medication Adherence ScalePsychometricsTreatment adherenceruxolitiniboral therapiesMedication AdherenceCohort StudiesTreatment complianceInternal medicineSurveys and QuestionnairesNitrilesmedicineHumansIn patientProspective StudiesProspective cohort studyMyelofibrosistreatment compliance8-item Morisky Medication Adherence Scale oral therapies ruxolitinib treatment compliance Adherencebusiness.industryHematologyJanus Kinase 1Janus Kinase 2Interim analysismedicine.disease8-item Morisky Medication Adherence Scale; Adherence; oral therapies; ruxolitinib; treatment compliancePyrimidinesOncologyAdherencePrimary MyelofibrosisPyrazolesObservational studybusinessmedicine.drugLeukemialymphoma
researchProduct

Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study

2019

Background: Non-adherence to medications is recognized as one of the most important and costly worldwide healthcare problems in the 21st century; according to an EU report, non-adherence to therapies is responsible for 194,500 deaths and costs €125 billion annually. Taking into account those data, the use of adherence measurements in clinical trials could be extremely useful, in order to better understand patients (pts) behaviours and outcomes. The 8-item Morisky Medication Adherence Scale (MMAS-8, Morisky DE et al, J Clin Hypertens,2008 - Krousel-Wood MA et al, Am J Manag Care 2009- Morisky DE et al, J Clin Epidemiol. 2011) is a widely used questionnaire to asses indirectly pts adherence t…

medicine.medical_specialtyIntention-to-treat analysisbusiness.industryImmunologyPsychological interventionCell BiologyHematologyManag careBiochemistryClinical trialInformed consentInternal medicineCohortmedicineObservational studySummary of Product CharacteristicsbusinessBlood
researchProduct